New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.» Read More
*Ablynx initially to get 20 mln euros, plus 10.7 mln for research. *Ablynx shares gain up to 6.9 pct. BRUSSELS, Feb 3- Belgian biotech company Ablynx has signed a deal with Merck& Co worth up to 1.7 billion euros to develop ways of triggering the body to fight cancer by itself.
Traders await Friday's jobs report and watch emerging markets to see if the selloff can be contained.
Cramer believes there’s always opportunity in the market. You simply have to know where to look.
Talking Squawk, the "Squawk Box" blog, provides tidbits, insights and sarcastic reflections on the WEEK THAT WAS and the WEEK TO COME.
Jan 29- After three years of seeing major drugs like Zyprexa for schizophrenia lose patent protection and wipe away billions of dollars in revenue, Eli Lilly and Co Chief Executive Officer John Lechleiter wants to change the game plan.
BASEL, Jan 29- Novartis is looking at options, such as joint ventures, for three smaller businesses to bring them in line with its world-leading pharmaceutical operations, it said on Wednesday, in a review due to be completed by the end of summer.
Jan 28- Merck& Co's experimental drug Ragwitek, a treatment for ragweed allergies, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday. About 30 million people in the United States suffer allergies to ragweed pollen, according to the FDA.
Jan 28- Merck& Co's experimental allergy drug, Ragwitek, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday. The panel voted 6 to 2, with one abstention, that data supported the drug's efficacy.
European equities closed lower on Monday, falling to their lowest levels in more than a month.
Some of the names on the move ahead of the open.
Jan 24- Bristol-Myers Squibb Co on Friday reported stronger-than-expected quarterly results, but its shares fell because of investors' jitters about the pace at which the company is developing a promising new combination of cancer drugs.
JOHANNESBURG, Jan 17- Global drug firms may threaten to cut their South African investments as part of a campaign against Pretoria's plans to overhaul its intellectual property laws to favour generic production, documents seen by Reuters show.
Jan 15- Merck& Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA is not bound to follow the advice of its advisory panels but typically does so.
SAN FRANCISCO, Jan 14- Merck& Co's researchers need to regain their confidence after an eight-year drought in developing important new medicines sapped employee morale, the company's recently hired research chief told Reuters.
*Shares in AstraZeneca rise 2 percent. LONDON, Jan 14- AstraZeneca expects to return to growth faster than analysts currently predict after a wave of drug patent expiries, with 2017 revenue likely to be broadly in line with the 2013 level.
*Merck up after FDA review, strategic options plans. "People are sitting on their hands, waiting for major results to figure out how strong this season may be," said Douglas DePietro, managing director at Evercore Partners in New York. DePietro was looking forward to results from JPMorgan Chase& Co and Wells Fargo& Co, both slated to report on Tuesday.
*Merck up after FDA review, strategic options plans. *Suntory Holdings to acquire Beam for $83.50 per share. "People are sitting on their hands, waiting for major results to figure out how strong this season may be," said Douglas DePietro, managing director at Evercore Partners in New York.
*Novartis may swap animal health, vaccines for Merck's OTC. *Novartis, Merck may each trade $5 bln in assets- Bloomberg. LONDON/ FRANKFURT, Jan 9- Novartis AG is discussing swapping its animal health and human vaccines businesses for Merck& Co Inc's over-the-counter products unit in a deal that could boost earnings at both companies.
Jan 8- Novartis AG is in talks with Merck& Co Inc to exchange its animal-health and human vaccines businesses for the drugmaker's over-the-counter health-products unit, Bloomberg reported, quoting people familiar with the matter. Novartis has not finalized a deal with Merck, and may choose another option, Bloomberg said.
ZURICH, Jan 8- Swiss drugmaker Roche has found an efficient way for complex antibody drugs to reach and penetrate the brain, raising the possibility of more effective treatments for diseases such as Alzheimer's.